CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice (Q42945868)

11 November 2017

CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice (English)

1 reference

11 November 2017

1 reference

1 reference

1 reference

Young Sun Kang

1

1 reference

11 November 2017

Mi Hwa Lee

2

1 reference

11 November 2017

Hye Kyoung Song

3

1 reference

11 November 2017

Gang Jee Ko

4

1 reference

11 November 2017

Oh Sung Kwon

5

1 reference

11 November 2017

Tae Kyung Lim

6

1 reference

11 November 2017

Sung Hwan Kim

7

1 reference

11 November 2017

Sang Youb Han

8

1 reference

11 November 2017

Kum Hyun Han

9

1 reference

11 November 2017

Ji Eun Lee

10

1 reference

11 November 2017

Jee Young Han

11

1 reference

11 November 2017

Hyoung Kyu Kim

12

1 reference

11 November 2017

Dae Ryong Cha

13

1 reference

11 November 2017

language of work or name

English

0 references

publication date

4 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

78

1 reference

11 November 2017

9

1 reference

11 November 2017

883-894

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2010.263

11 November 2017

0 references

cites work

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Leukocyte recruitment and vascular injury in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Inflammation and diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

The role of macrophages in diabetic glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

The role of chemokines and chemokine receptors in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Role of aldosterone in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Obesity-induced inflammation: a metabolic dialogue in the language of inflammation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

The metabolic syndrome and adipocytokines

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Lipid homeostasis in macrophages - implications for atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.2010.263

1 reference

7 January 2021

Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

The hormone resistin links obesity to diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Specific up-regulation of CRH or AVP secretion by acetylcholine or lipopolysaccharide in inflammatory susceptible Lewis rat fetal hypothalamic cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Development of insulin-responsive glucose uptake and GLUT4 expression in differentiating human adipocyte precursor cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

The morphology and metabolism of intraabdominal adipose tissue in men

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Diet induction of monocyte chemoattractant protein-1 and its impact on obesity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.263

7 January 2021

Identifiers

DOI

10.1038/KI.2010.263

1 reference

Dimensions Publication ID

11 November 2017

0 references

1 reference